Craft

Bicycle Therapeutics

Stock Price

$24.8

2024-10-28

Market Capitalization

$1.7 B

2024-10-28

Revenue

$27 M

FY, 2023

Bicycle Therapeutics Summary

Company Summary

Overview
Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops cancer therapies. It offers bicyclic peptide technology, immuno-oncology, radio, and toxin conjugate pipelines.
Type
Public
Status
Active
Founded
2009
HQ
Cambridge, GB | view all locations
Website
https://www.bicycletherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Kevin Lee

    Kevin Lee, Chief Executive Officer and Director

  • Michael Skynner

    Michael Skynner, Chief Technology Officer

  • Nigel Crockett

    Nigel Crockett, Chief Business Officer

  • Alistair Milnes

    Alistair Milnes, Chief Operating Officer

Operating MetricsView all

Patents

103
4.6%

FY, 2021

Trademarks

46

FY, 2021

LocationsView all

2 locations detected

  • Cambridge, England HQ

    United Kingdom

    Blocks A & B Portway Building, Granta Park

  • Cambridge, MA

    United States

    35 Cambridgepark Drive

Bicycle Therapeutics Financials

Summary Financials

Revenue (Q2, 2024)
$9.4M
Net income (Q2, 2024)
($39.8M)
Cash (Q2, 2024)
$961.4M
EBIT (Q2, 2024)
($46.6M)
Enterprise value
$792.4M

Footer menu